4//SEC Filing
RUFFOLO ROBERT R 4
Accession 0001415889-21-003398
CIK 0001821323other
Filed
Jul 1, 8:00 PM ET
Accepted
Jul 2, 4:16 PM ET
Size
8.8 KB
Accession
0001415889-21-003398
Insider Transaction Report
Form 4
RUFFOLO ROBERT R
Director
Transactions
- Exercise/Conversion
Common Stock
2021-07-01$0.57/sh+6,750$3,847→ 6,750 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-07-01−6,750→ 48,805 totalExercise: $0.57Exp: 2026-07-13→ Common Stock (6,750 underlying) - Sale
Common Stock
2021-07-01$10.36/sh−6,750$69,930→ 0 total
Footnotes (3)
- [F1]The reported transaction was effected pursuant to a Rule 10b5-1 trading plan.
- [F2]The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.17 to $10.73. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- [F3]The option vested as to 25% of the underlying shares of common stock on July 14, 2017, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each quarter following such date until the option is fully vested.
Documents
Issuer
Sigilon Therapeutics, Inc.
CIK 0001821323
Entity typeother
Related Parties
1- filerCIK 0001187308
Filing Metadata
- Form type
- 4
- Filed
- Jul 1, 8:00 PM ET
- Accepted
- Jul 2, 4:16 PM ET
- Size
- 8.8 KB